Novo Holdings sets sights on more acquisitions in hot bioindustry sector

Denmarks biggest fund, Novo Holdings, has in a few years built a large portfolio of companies in the biotech industry. More to come, says the man in charge of it all.

Kasim Kutay, CEO at Novo Holdings, sees big opportunities in the bioindustry. | Photo: Kenneth Lysbjerg Koustrup/ERH

BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY CATHERINE BRETT AND DANIEL PEDERSEN

Published: 13.09.21 at 15:40

The biggest-by-far fund in Denmark is buying green with all of its power, and even more acquisitions could be coming.

The portfolio has been built in just a few years, from almost nothing to now comprising a number of companies spanning everything from bricks made from waste to the future of aviation fuel, in addition to products aiming to push out pesticides for good.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.